6.640SEK+1.07%Mkt Cap: 91.03M SEKP/E: —Last update: 2026-05-13
OncoZenge AB (publ), a pharmaceutical company, engages in the development of treatment for pain relief in patients suffering from oral pain caused by radiation therapy and chemotherapy for cancer in Sweden. It offers Bup…
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Valuation
P/E (Trailing)—
P/E (Forward)-32.40
PEG—
P/B9.67
P/S32.70
EV/EBITDA—
EV/Revenue30.80
EPS (TTM)-1.31
EPS (Forward)-0.20
Cash Flow & Leverage
FCF Yield-7.78%
FCF Margin-254.47%
Operating CF-13.06M SEK
CapEx (TTM)—
Net Debt/EBITDA—
Net Debt3.79M SEK
Technical
SMA 505.927 (+12.0%)
SMA 2005.984 (+11.0%)
Beta1.33
S&P 52W Chg24.23%
Avg Vol (30d)20.47K
Avg Vol (10d)27.19K
Technical Indicators
RSI (14)61.6
MACD0.1695
MACD Signal0.1175
MACD Hist.+0.0520
BB Upper6.644 SEK
BB Middle6.115 SEK
BB Lower5.586 SEK
BB Width17.30%
ATR (14)0.4581 SEK
Vol Ratio (20d)0.17x
52W Range
4.00042% of range10.28
52W High10.28 SEK
52W Low4.000 SEK
Profitability
Gross Margin100.00%
EBITDA Margin0.00%
Profit Margin-598.35%
Oper. Margin-974800.00%
ROE-188.04%
ROA-65.33%
Revenue Growth—
Earnings Growth—
Balance Sheet
Debt/Equity0.88
Current Ratio1.01
Quick Ratio0.74
Book Value/Sh0.6700 SEK
Cash/Share0.2940 SEK
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 SEK
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Ownership
Shares Out.14.05M
Float4.43M
Insiders45.10%
Institutions10.58%
Analyst Consensus
Rating—
Target (Mean)11.50 SEK
Target Range11.50 SEK – 11.50 SEK
# Analysts1
Company
Market Cap91.03M SEK
Enterprise Value85.74M SEK
Revenue (TTM)2.78M SEK
Gross Profit2.78M SEK
Net Income (TTM)-15.94M SEK
Revenue/Share0.2300 SEK
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees—
Last Price6.640 SEK
CountrySE
SectorHealthcare
IndustryBiotechnology
ISIN—